Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C Virus genotype 1 infection. The number of patients who received this treatment resulted generally lower than expected. We investigated, among naïve patients, number and characteristics of treatment candidates who were started on triple or dual therapy in comparison to those who were deferred.
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience / Mangia, Alessandra; Cenderello, Giovanni; Orlandini, Alessandra; Piazzolla, Valeria; Picciotto, Antonio; Zuin, Massimo; Ciancio, Alessia; Brancaccio, Giuseppina; Forte, Paolo; Carretta, Vito; Zignego, Anna Linda; Minerva, Nicola; Brindicci, Gaetano; Marignani, Massimo; Baroni, Gianluca Svegliati; Bertino, Gaetano; Cuccorese, Giuseppe; Mottola, Leonardo; Ripoli, Maria; Pirisi, Mario. - In: PLOS ONE. - ISSN 1932-6203. - 9:10(2014), p. e110284. [10.1371/journal.pone.0110284]
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience
Baroni, Gianluca SvegliatiMembro del Collaboration Group
;
2014-01-01
Abstract
Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C Virus genotype 1 infection. The number of patients who received this treatment resulted generally lower than expected. We investigated, among naïve patients, number and characteristics of treatment candidates who were started on triple or dual therapy in comparison to those who were deferred.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.